Table 1.
Patient demographics and disease characteristics at baseline
| RCT patientsa | EMR patients | ||
|---|---|---|---|
| Placebo (N = 411) | All patients (N = 10,523) | All episodes (N = 10,942) | |
| Women, n (%) | 168 (41) | 7,565 (72) | 7,825 (72) |
| Age, mean years (SD) | 62.5 (10.1) | ||
| Age ≥65 years, n (%) | 175 (43) | 4,147 (39) | 4,321 (39) |
| Race, White n (%) | 397 (97) | ||
| Tumor type, n (%) | |||
| Breast | 18 (4) | 4,353 (41) | 4,418 (40) |
| Gastrointestinal | 14 (3) | ||
| Genitourinary | 5 (1) | ||
| Gynecologic | 12 (3) | 899 (9) | 961 (9) |
| Hematologic | 56 (14) | ||
| Lung | 297 (72) | 3,071 (29) | 3,257 (30) |
| Other | 9 (2) | 2,200 (21) | 2,306 (21) |
| Stage, n (%) | |||
| I/II or lower/limited | 39 (10) | ||
| III/IV or higher/extensive | 361 (88) | ||
| Other | 6 (1) | ||
| Unknown | 5 (1) | ||
| Chemotherapy regimen, n (%) | |||
| Anthracycline | 3,017 (29) | 3,050 (28) | |
| Taxane | 7,075 (67) | 7,269 (66) | |
| Platinum | 6,100 (58) | 6,408 (59) | |
| Gemcitabine | 1,465 (14) | 1,504 (14) | |
| Hemoglobin, mean g/dL (SD) | 11.26 (0.98) | ||
aIncludes only patients who had hemoglobin ≥10 g/dL and had hemoglobin <10 g/dL at least once during the study
SD standard deviation RCT randomized controlled trials EMR electronic medical records